{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Abeyasinghe PM"],"funding":["Medical Research Council","NINDS NIH HHS","National Health and Medical Research Council","Wellcome Trust"],"pagination":["2282-2292"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8590922"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(10)"],"pubmed_abstract":["<h4>Background</h4>Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants.<h4>Objective</h4>The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups.<h4>Methods</h4>Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 "],"journal":["Movement disorders : official journal of the Movement Disorder Society"],"pubmed_title":["Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers."],"pmcid":["PMC8590922"],"funding_grant_id":["U01 NS105509","UKDRI-1008/2","200181/Z/15/Z","606650","U01 NS103475","R01 NS040068"],"pubmed_authors":["Razi A","Poudel GR","Abeyasinghe PM","Tabrizi SJ","Pustina D","Georgiou-Karistianis N","Long JD","Paulsen JS"],"additional_accession":[]},"is_claimable":false,"name":"Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers.","description":"<h4>Background</h4>Potential therapeutic targets and clinical trials for Huntington's disease have grown immensely in the last decade. However, to improve clinical trial outcomes, there is a need to better characterize profiles of signs and symptoms across different epochs of the disease to improve selection of participants.<h4>Objective</h4>The objective of the present study was to best distinguish longitudinal trajectories across different Huntington's disease progression groups.<h4>Methods</h4>Clinical and morphometric imaging data from 1082 participants across IMAGE-HD, TRACK-HD, and PREDICT-HD studies were combined, with longitudinal times ranging between 1 and 10 years. Participants were classified into 4 groups using CAG and age product. Using multivariate linear mixed modeling, 63 ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-04T19:52:44.458Z","creation":"2025-02-19T02:24:11.026Z"},"accession":"S-EPMC8590922","cross_references":{"pubmed":["34014005"],"doi":["10.1002/mds.28650"]}}